Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium
- Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis
- aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel
EINDHOVEN, The Netherlands, 17 April 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces two presentations on its ground-breaking treatment options during the 46th Annual Charing Cross Symposium, the leading symposium in the field of vascular and endovascular education being held in London from 23rd-25th April 2024.
